Skip to content
2000
Volume 25, Issue 16
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

The diagnosis of adrenocortical tumors remains clinically challenging due to overlapping morphological and functional features between benign, malignant, and hormonally active lesions. Malignant and functional tumors are frequently associated with poor prognosis. Traditional morphological imaging methods, such as CT and MRI, cannot reliably distinguish lesion types. Recent evidence suggests that molecular imaging targeting C-X-C motif chemokine receptor 4 (CXCR4), a biomarker overexpressed in functional adenomas and adrenocortical carcinomas (ACC), offers enhanced diagnostic precision. For instance, 68Ga-pentixafor, a CXCR4-targeted radiotracer, demonstrates high accuracy in distinguishing functional from nonfunctional lesions and unilateral from bilateral subtypes in primary aldosteronism. Depending on the level of tracer uptake, it may also be possible to guide therapeutic decisions and assess treatment response. For Cushing's syndrome, particularly cortisol-producing adenomas, CXCR4 imaging facilitates the localization of adrenal lesions, reducing dependency on invasive techniques. In ACC, overexpression of CXCR4 enables metastasis detection, and its complementary use with 18F-FDG PET/CT improves lesion detection. Furthermore, the theranostic agent 177Lu/90Y-Pentixather demonstrates considerable promise for CXCR4-directed Endoradiotherapy (ERT) in advanced ACC. This review aimed to summarize the advancements of CXCR4-targeted molecular imaging in adrenocortical tumors and ERT in ACC.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mrmc/10.2174/0113895575408753250904112417
2025-09-08
2026-02-26

  • From This Site

    /content/journals/mrmc/10.2174/0113895575408753250904112417
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SongJ.H. ChaudhryF.S. Mayo-SmithW.W. The incidental adrenal mass on CT: Prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy.AJR Am. J. Roentgenol.200819051163116810.2214/AJR.07.2799 18430826
     [Google Scholar]
  2. ZeigerM.A. ThompsonG.B. DuhQ.Y. HamrahianA.H. AngelosP. ElarajD. FishmanE. KharlipJ. HamrahianA.H. GarberJ.R. MechanickJ.I. DemeureM.J. InabnetW.B. American association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of Adrenal incidentalomas: Executive summary of recommendations.Endocr. Pract.200915545045310.4158/EP.15.5.450 19632968
     [Google Scholar]
  3. FassnachtM. TsagarakisS. TerzoloM. TabarinA. SahdevA. Newell-PriceJ. PelsmaI. MarinaL. LorenzK. BancosI. ArltW. DekkersO.M. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European network for the study of adrenal tumors.Eur. J. Endocrinol.20231891G1G4210.1093/ejendo/lvad066 37318239
     [Google Scholar]
  4. BourdeauI. El GhorayebN. GagnonN. LacroixA. Management of Endocrine disease: Differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas.Eur. J. Endocrinol.20181792R57R6710.1530/EJE‑18‑0296 29748231
     [Google Scholar]
  5. DinnesJ. BancosI. Ferrante di RuffanoL. ChortisV. DavenportC. BaylissS. SahdevA. GuestP. FassnachtM. DeeksJ.J. ArltW. Management of endocrine disease: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: A systematic review and meta-analysis.Eur. J. Endocrinol.20161752R51R6410.1530/EJE‑16‑0461 27257145
     [Google Scholar]
  6. PeñaC.S. BolandG.W.L. HahnP.F. LeeM.J. MuellerP.R. Characterization of indeterminate (lipid-poor) adrenal masses: Use of washout characteristics at contrast-enhanced CT.Radiology2000217379880210.1148/radiology.217.3.r00dc29798 11110946
     [Google Scholar]
  7. SeoJ.M. ParkB.K. ParkS.Y. KimC.K. Characterization of lipid-poor adrenal adenoma: Chemical-shift MRI and washout CT.AJR Am. J. Roentgenol.201420251043105010.2214/AJR.13.11389 24758658
     [Google Scholar]
  8. Mayo-SmithW.W. SongJ.H. BolandG.L. FrancisI.R. IsraelG.M. MazzagliaP.J. BerlandL.L. PandharipandeP.V. Management of incidental Adrenal masses: A white paper of the ACR incidental findings committee.J. Am. Coll. Radiol.20171481038104410.1016/j.jacr.2017.05.001 28651988
     [Google Scholar]
  9. YenR.F. WuV.C. LiuK.L. ChengM.F. WuY.W. ChuehS.C. LinW.C. WuK.D. TzenK.Y. LuC.C. 131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results.J. Nucl. Med.200950101631163710.2967/jnumed.109.064873 19759122
     [Google Scholar]
  10. RenX. ChengG. WangZ. Advances in the molecular imaging of primary aldosteronism.Ann. Nucl. Med.202337843344110.1007/s12149‑023‑01851‑y 37393373
     [Google Scholar]
  11. HeX. CaoiliE.M. AvramA.M. MillerB.S. ElseT. 18F-FDG-PET/CT evaluation of indeterminate Adrenal masses in noncancer patients.J. Clin. Endocrinol. Metab.202110651448145910.1210/clinem/dgab005 33524123
     [Google Scholar]
  12. SchaafsmaM. BerendsA.M.A. LinksT.P. BrouwersA.H. KerstensM.N. The diagnostic value of 18F-FDG PET/CT scan in characterizing Adrenal tumors.J. Clin. Endocrinol. Metab.202310892435244510.1210/clinem/dgad138 36948598
     [Google Scholar]
  13. VosE.L. GrewalR.K. RussoA.E. Reidy-LagunesD. UntchB.R. GavaneS.C. BoucaiL. GeerE. GopalanA. ChouJ.F. CapanuM. StrongV.E. Predicting malignancy in patients with adrenal tumors using 18 F-FDG-PET/CT SUVmax.J. Surg. Oncol.202012281821182610.1002/jso.26203 32914407
     [Google Scholar]
  14. AkkuşG. GüneyI.B. OkF. EvranM. IzolV. ErdoğanŞ. BayazıtY. SertM. TetikerT. Diagnostic efficacy of 18F-FDG PET/CT in patients with adrenal incidentaloma.Endocr. Connect.20198783884510.1530/EC‑19‑0204 31137014
     [Google Scholar]
  15. BergströmM. JuhlinC. BonaseraT.A. SundinA. RastadJ. AkerströmG. LångströmB. PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate.J. Nucl. Med.2000412275282 10688111
     [Google Scholar]
  16. SoinioM. LuukkonenA.K. SeppänenM. KemppainenJ. SeppänenJ. PienimäkiJ.P. LeijonH. VesterinenT. ArolaJ. LanttoE. HelinS. TikkanenI. MetsoS. MirttiT. HeiskanenI. NorvioL. TiikkainenM. TikkanenT. SaneT. VälimäkiM. Gomez-SanchezC.E. PörstiI. NuutilaP. NevalainenP.I. MatikainenN. Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism.Eur. J. Endocrinol.2020183653955010.1530/EJE‑20‑0532 33055298
     [Google Scholar]
  17. Chen CardenasS.M. SanthanamP. 11C-metomidate PET in the diagnosis of adrenal masses and primary aldosteronism: A review of the literature.Endocrine202070347948710.1007/s12020‑020‑02474‑3 32886316
     [Google Scholar]
  18. PuarT.H. KhooC.M. TanC.J. TongA.K.T. TanM.C.S. TeoA.E.D. NgK.S. WongK.M. ReilhacA. O’DohertyJ. Gomez-SanchezC.E. KekP.C. YeeS. TanA.W.K. ChuahM.B. LeeD.H.M. WangK.W. ZhengC.Q. ShiL. RobinsE.G. FooR.S.Y. 11C-Metomidate PET-CT versus adrenal vein sampling to subtype primary aldosteronism: A prospective clinical trial.J. Hypertens.202240611791188for the PA CURE investigators.10.1097/HJH.000000000000313235703880
     [Google Scholar]
  19. WuX. SenanayakeR. GoodchildE. BashariW.A. SalsburyJ. CabreraC.P. ArgentesiG. O’TooleS.M. MatsonM. KooB. ParvantaL. HilliardN. KosmoliaptsisV. MarkerA. BerneyD.M. TanW. FooR. MeinC.A. WozniakE. SavageE. SahdevA. BirdN. LaycockK. BorosI. HaderS. WarnesV. GillettD. DawnayA. AdeyeyeE. PreteA. TaylorA.E. ArltW. BhuvaA.N. AigbirhioF. ManistyC. McIntoshA. McConnachieA. CruickshankJ.K. CheowH. GurnellM. DrakeW.M. BrownM.J. [11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: A prospective, within-patient trial.Nat. Med.202329119020210.1038/s41591‑022‑02114‑5 36646800
     [Google Scholar]
  20. ChifuI. HeinzeB. FussC.T. LangK. KroissM. KircherS. RonchiC.L. AltieriB. SchirbelA. FassnachtM. HahnerS. Impact of the chemokine receptors CXCR4 and CXCR7 on clinical outcome in Adrenocortical carcinoma.Front. Endocrinol.20201159787810.3389/fendo.2020.597878 33281749
     [Google Scholar]
  21. YuJ. ZhouX. ShenL. CXCR4-Targeted radiopharmaceuticals for the imaging and therapy of malignant tumors.Molecules20232812470710.3390/molecules28124707 37375261
     [Google Scholar]
  22. HeinzeB. FussC.T. MulateroP. BeuschleinF. ReinckeM. MustafaM. SchirbelA. DeutschbeinT. WilliamsT.A. RhayemY. QuinklerM. RayesN. MonticoneS. WildV. Gomez-SanchezC.E. ReisA.C. PetersennS. WesterH.J. KropfS. FassnachtM. LangK. HerrmannK. BuckA.K. BluemelC. HahnerS. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for molecular imaging of Aldosterone-Producing Adenoma.Hypertension201871231732510.1161/HYPERTENSIONAHA.117.09975 29279316
     [Google Scholar]
  23. DingJ. TongA. ZhangY. WenJ. ZhangH. HackerM. HuoL. LiX. Functional characterization of Adrenocortical masses in nononcologic patients using 68 Ga-Pentixafor.J. Nucl. Med.202263336837510.2967/jnumed.121.261964 34301781
     [Google Scholar]
  24. KaemmererD. SängerJ. ArsenicR. D’HaeseJ.G. NeumannJ. Schmitt-GraeffA. WirtzR.M. SchulzS. LuppA. Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas.Oncotarget2017852899588996910.18632/oncotarget.21194 29163802
     [Google Scholar]
  25. BurgerJ.A. PeledA. CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers.Leukemia2009231435210.1038/leu.2008.299 18987663
     [Google Scholar]
  26. KircherM. HerhausP. SchotteliusM. BuckA.K. WernerR.A. WesterH.J. KellerU. LapaC. CXCR4-directed theranostics in oncology and inflammation.Ann. Nucl. Med.201832850351110.1007/s12149‑018‑1290‑8 30105558
     [Google Scholar]
  27. WalenkampA.M.E. LapaC. HerrmannK. WesterH.J. CXCR4 ligands: The next big hit?J. Nucl. Med.201758Suppl. 277S82S10.2967/jnumed.116.186874 28864616
     [Google Scholar]
  28. ChenZ. XueQ. YaoS. Nuclear medicine application of Pentixafor/Pentixather targeting CXCR4 for imaging and therapy in related disease.Mini Rev. Med. Chem.202323778780310.2174/1389557523666221216095821 36529918
     [Google Scholar]
  29. GourniE. DemmerO. SchotteliusM. D’AlessandriaC. SchulzS. DijkgraafI. SchumacherU. SchwaigerM. KesslerH. WesterH.J. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.J. Nucl. Med.201152111803181010.2967/jnumed.111.098798 22045709
     [Google Scholar]
  30. WeissI.D. JacobsonO. Molecular imaging of chemokine receptor CXCR4.Theranostics201331768410.7150/thno.4835 23382787
     [Google Scholar]
  31. BuckA.K. SerflingS.E. LindnerT. HänscheidH. SchirbelA. HahnerS. FassnachtM. EinseleH. WernerR.A. CXCR4-targeted theranostics in oncology.Eur. J. Nucl. Med. Mol. Imaging202249124133414410.1007/s00259‑022‑05849‑y 35674738
     [Google Scholar]
  32. MossoL. CarvajalC. GonzálezA. BarrazaA. AvilaF. MonteroJ. HueteA. GederliniA. FardellaC.E. Primary aldosteronism and hypertensive disease.Hypertension200342216116510.1161/01.HYP.0000079505.25750.11 12796282
     [Google Scholar]
  33. MonticoneS. BurrelloJ. TizzaniD. BertelloC. ViolaA. BuffoloF. GabettiL. MengozziG. WilliamsT.A. RabbiaF. VeglioF. MulateroP. Prevalence and clinical manifestations of primary Aldosteronism encountered in primary care practice.J. Am. Coll. Cardiol.201769141811182010.1016/j.jacc.2017.01.052 28385310
     [Google Scholar]
  34. LadurnerR. SommereyS. BuechnerS. DietzA. DegenhartC. HallfeldtK. GallwasJ. Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism.Eur. J. Clin. Invest.201747537237710.1111/eci.12746 28299775
     [Google Scholar]
  35. LimV. GuoQ. GrantC.S. ThompsonG.B. RichardsM.L. FarleyD.R. YoungW.F. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism.J. Clin. Endocrinol. Metab.20149982712271910.1210/jc.2013‑4146 24796926
     [Google Scholar]
  36. FunderJ.W. CareyR.M. FardellaC. Gomez-SanchezC.E. ManteroF. StowasserM. YoungW.F. MontoriV.M. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline.J. Clin. Endocrinol. Metab.20089393266328110.1210/jc.2008‑0104 18552288
     [Google Scholar]
  37. FunderJ.W. CareyR.M. ManteroF. MuradM.H. ReinckeM. ShibataH. StowasserM. YoungW.F. The management of primary Aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline.J. Clin. Endocrinol. Metab.201610151889191610.1210/jc.2015‑4061 26934393
     [Google Scholar]
  38. BuffoloF. MonticoneS. WilliamsT. RossatoD. BurrelloJ. TettiM. VeglioF. MulateroP. Subtype diagnosis of primary Aldosteronism: Is adrenal vein sampling always necessary?Int. J. Mol. Sci.201718484810.3390/ijms18040848 28420172
     [Google Scholar]
  39. RossiG.P. MaiolinoG. SecciaT.M. Adrenal venous sampling.Endocrinol. Metab. Clin. North Am.201948484385810.1016/j.ecl.2019.08.012 31655780
     [Google Scholar]
  40. RossiG.P. RossittoG. AmarL. AziziM. RiesterA. ReinckeM. DegenhartC. WidimskyJ. NaruseM. DeinumJ. Schultze KoolL. KocjanT. NegroA. RossiE. KlineG. TanabeA. SatohF. Christian RumpL. VonendO. WillenbergH.S. FullerP.J. YangJ. CheeN.Y.N. MagillS.B. ShafigullinaZ. QuinklerM. OliverasA. Dun WuK. WuV.C. KratkaZ. BarbieroG. BattistelM. ChangC.C. VanderrieleP.E. PessinaA.C. Clinical outcomes of 1625 patients with primary Aldosteronism subtyped with adrenal vein sampling.Hypertension201974480080810.1161/HYPERTENSIONAHA.119.13463 31476901
     [Google Scholar]
  41. DingJ. TongA. ZhangY. WenJ. HuoL. Intense 68Ga-Pentixafor activity in Aldosterone-Producing adrenal adenomas.Clin. Nucl. Med.202045433633910.1097/RLU.0000000000002946 32108693
     [Google Scholar]
  42. DingJ. ZhangY. WenJ. ZhangH. WangH. LuoY. PanQ. ZhuW. WangX. YaoS. KreisslM.C. HackerM. TongA. HuoL. LiX. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism.Eur. J. Nucl. Med. Mol. Imaging202047112656266510.1007/s00259‑020‑04722‑0 32206838
     [Google Scholar]
  43. ZhengY. LongT. PengN. ZhenM. YeQ. ZhangZ. HeY. ChenZ. GanY. LuoM. LiC. LiuZ. GuoM. WangM. LuoX. HuS. LiuL. JiangT. The value of targeting CXCR4 With 68Ga-Pentixafor PET/CT for subtyping primary Aldosteronism.J. Clin. Endocrinol. Metab.2023109117118210.1210/clinem/dgad421 37477496
     [Google Scholar]
  44. GaoY. DingJ. CuiY. LiT. SunH. ZhaoD. ZhangY. HuoL. TongA. Functional nodules in primary aldosteronism: identification of CXCR4 expression with 68Ga-pentixafor PET/CT.Eur. Radiol.2022332996100310.1007/s00330‑022‑09058‑x 36070092
     [Google Scholar]
  45. ZhangX. SongY. JingY. HuJ. ShenH. ZhangA. HeW. FengZ. YangY. PangH. LiQ. YangS. MeiM. LuoS. LiaoK. ZhangY. HeY. HeY. XiaoM. PengB. Comparison of different diagnostic criteria of 68Ga-Pentixafor PET/CT for the Classification of Primary Aldosteronism.J. Clin. Endocrinol. Metab.20251108e2583e259010.1210/clinem/dgae747 39626105
     [Google Scholar]
  46. MengX. QuanZ. FanL. ZhangM. LiG. XuM. WangJ. MaW. YangW. YangB. WangJ. KangF. Added value of multiparametric MRI for diagnosing subcentimeter functional adrenal nodules in primary aldosteronism using CXCR4-targeted PET/MRI.Eur. J. Nucl. Med. Mol. Imaging202510.1007/s00259‑025‑07415‑8 40536566
     [Google Scholar]
  47. DingJ. LiX. LiuS. GaoY. ZhengG. HackerM. ZhangY. TongA. HuoL. Clinical value of 68 Ga-Pentixafor PET/CT in subtype diagnosis of primary Aldosteronism patients with Adrenal micronodules.J. Nucl. Med.202465111712410.2967/jnumed.123.266061 38050127
     [Google Scholar]
  48. PoschenriederA. OslT. SchotteliusM. HoffmannF. WirtzM. SchwaigerM. WesterH.J. First 18F-Labeled Pentixafor-Based imaging agent for PET imaging of CXCR4 expression in vivo.Tomography201622859310.18383/j.tom.2016.00130 30042959
     [Google Scholar]
  49. HeL. YangY. CaoX. ZhuX. LiuN. ChenX. ZhangJ. ZhangW. [ 18 F]AlF-NOTA-pentixather PET/CT of CXCR4 in patients with suspected primary hyperaldosteronism.Theranostics202414197281729110.7150/thno.100848 39659571
     [Google Scholar]
  50. HuJ. XuT. ShenH. SongY. YangJ. ZhangA. DingH. XingN. LiZ. QiuL. MaL. YangY. FengZ. DuZ. HeW. SunY. CaiJ. LiQ. ChenY. YangS. MeiM. LuoS. LiaoK. ZhangY. HeY. HeY. PengB. XiaoM. Accuracy of Gallium-68 Pentixafor positron emission tomography–computed tomography for subtyping diagnosis of primary Aldosteronism.JAMA Netw. Open202362e225560910.1001/jamanetworkopen.2022.55609 36795418
     [Google Scholar]
  51. YiT. LuD. CuiY. ZhangZ. YangX. ZhangJ. QiuL. WengH. LiuL. DuanX. ZhaoG. MaW. GaoY. FanY. 68Ga-pentixafor PET/CT is a issueary method for primary Aldosteronism subtyping compared with adrenal vein sampling.Mol. Imaging Biol.202527114215010.1007/s11307‑024‑01976‑0 39715984
     [Google Scholar]
  52. YinX. AiK. LuoJ. LiuW. MaX. ZhouL. XiangX. SuX. WangY. LiY. A comparison of the performance of 68Ga-Pentixafor PET/CT versus adrenal vein sampling for subtype diagnosis in primary aldosteronism.Front. Endocrinol.202415129177510.3389/fendo.2024.1291775 38419957
     [Google Scholar]
  53. EnkeJ.S. RitzelK. AsbachE. ReitsamN.G. MärklB. KnöselT. BrüdgamD. KircherM. PfobC.H. BundschuhR.A. RinscheidA. NittbaurB. WienandG. SchotteliusM. ReinckeM. LapaC. DierksA. C-X-C Motif Chemokine Receptor 4–Directed scintigraphy using [ 99m Tc]Tc-Pentixatec in primary Aldosteronism: A proof-of-concept study.J. Nucl. Med.202465101640164410.2967/jnumed.124.268169 39237344
     [Google Scholar]
  54. Chaman BazA.H. van de WielE. GroenewoudH. ArntzM. GotthardtM. DeinumJ. LangenhuijsenJ. CXCR4-directed [ 68 Ga]Ga-PentixaFor PET/CT versus adrenal vein sampling performance: A study protocol for a randomised two-step controlled diagnostic trial ultimately comparing hypertenSion outcome in primary aldosteronism (CASTUS).BMJ Open2022128e06077910.1136/bmjopen‑2022‑060779 35998969
     [Google Scholar]
  55. LuN. ChenL. YuF. XiaoZ. XingD. ZhongJ. ZengD. WangY. TangS. HeY. ZheM. Evaluating the value of chemokine receptor type 4–targeted PET imaging in diagnosing primary aldosteronism lateralization: A comparison with adrenal venous sampling.Surgery202518110915610.1016/j.surg.2025.109156 39919695
     [Google Scholar]
  56. ZuoR. LiuS. LiW. XiaZ. XuL. PangH. Clinical value of 68Ga-pentixafor PET/CT in patients with primary aldosteronism and bilateral lesions: Preliminary results of a single-centre study.EJNMMI Res.20241416110.1186/s13550‑024‑01125‑2 38965078
     [Google Scholar]
  57. ZuoR. LiuS. RenX. LiW. XiaZ. XuL. PangH. Typing diagnostic value of 68Ga-pentixafor PET/CT for patients with primary aldosteronism and unilateral nodules.Endocrine202487131432410.1007/s12020‑024‑04024‑7 39251468
     [Google Scholar]
  58. ZuoR. LiuS. RenX. LiW. XiaZ. XuL. PangH. Clinical utility of dual-time 68 Ga-Pentixafor PET/CT in diagnosing and subtyping primary Aldosteronism.Clin. Endocrinol.2025102549950910.1111/cen.15204 39865783
     [Google Scholar]
  59. ChatterjeeS. Behnam AzadB. NimmagaddaS. The intricate role of CXCR4 in cancer.Adv. Cancer Res.2014124318210.1016/B978‑0‑12‑411638‑2.00002‑1 25287686
     [Google Scholar]
  60. BoulkrounS. Fernandes-RosaF.L. ZennaroM.C. Molecular and cellular mechanisms of Aldosterone producing adenoma development.Front. Endocrinol.201569510.3389/fendo.2015.00095 26124749
     [Google Scholar]
  61. PawigL. KlasenC. WeberC. BernhagenJ. NoelsH. Diversity and inter-connections in the CXCR4 chemokine receptor/ligand family: Molecular perspectives.Front. Immunol.2015642910.3389/fimmu.2015.00429 26347749
     [Google Scholar]
  62. WangM. ZhangJ. WuB. ZhangC. The role of 68Ga-Pentixafor PET in primary Aldosteronism: A systematic review and meta-analysis.Clin. Transl. Imaging202412332733610.1007/s40336‑023‑00610‑3
     [Google Scholar]
  63. GruberS. BeuschleinF. Hypokalemia and the prevalence of primary Aldosteronism.Horm. Metab. Res.202052634735610.1055/a‑1134‑4980 32252108
     [Google Scholar]
  64. WilliamsT.A. ReinckeM. Pathophysiology and histopathology of primary aldosteronism.Trends Endocrinol. Metab.2022331364910.1016/j.tem.2021.10.002 34743804
     [Google Scholar]
  65. ZhengG. DingJ. GaoY. LiuS. YanX. WangW. ZhaoY. WangZ. HuoL. TongA. ZhangY. 68Ga-pentixafor PET/CT in guiding surgical management of primary aldosteronism.J. Clin. Transl. Endocrinol.20253910038410.1016/j.jcte.2025.100384 39926105
     [Google Scholar]
  66. ShaoS. XuH. XingZ. HongY. YinX. LuoJ. AiK. SuX. MaX. LiY. The prognostic value of CXCR4 PET/CT imaging in unilateral primary aldosteronism patients after adrenalectomy.EJNMMI Res.20251514110.1186/s13550‑025‑01242‑6 40246740
     [Google Scholar]
  67. LiM. GuanL. YangL. LiW. XiaZ. MaoM. PangH. 68Ga-Pentixafor PET/CT for the assessment of therapeutic outcomes following superselective adrenal arterial embolization in patients with primary aldosteronism.EJNMMI Res.2025151510.1186/s13550‑024‑01194‑3 39821475
     [Google Scholar]
  68. ZhengW.C. ChenS.M. QiuQ.R. LiX.D. LinF. ShenX.M. FangZ.F. XueY.T. LinB. SunX.L. ZhengQ.S. WeiY. LinY.P. XiongH. XueX.Y. KeZ.B. XuN. Total or partial adrenalectomy for aldosterone-producing adenoma: Can 68Ga-Pentixafor PET/CT predict surgical outcomes?Eur. J. Nucl. Med. Mol. Imaging202552103632364210.1007/s00259‑025‑07244‑9 40183955
     [Google Scholar]
  69. TanL. ChenT. ZhangW. ShenS. TianH. ZhuY. TianR. RenY. CXCR4-directed PET with 68Ga-pentixafor versus adrenal vein sampling for the diagnosis of unilateral primary aldosteronism.Endocrine202589260361310.1007/s12020‑025‑04236‑5 40388084
     [Google Scholar]
  70. DingJ. TongA. ZhangY. ZhangH. HuoL. Cortisol-producing Adrenal Adenomas with intense activity on 68Ga-Pentixafor PET/CT.Clin. Nucl. Med.202146435035210.1097/RLU.0000000000003503 33492858
     [Google Scholar]
  71. DingJ. TongA. HackerM. FengM. HuoL. LiX. Usefulness of 68Ga-Pentixafor PET/CT on diagnosis and management of Cushing syndrome.Clin. Nucl. Med.202247866967610.1097/RLU.0000000000004244 35452014
     [Google Scholar]
  72. WuY. WuY. YaoB. RenS. WuS. RuiW. HeM. ZhangS. YuY. YeH. ZhangZ. YeZ. HanR. QiaoN. ZhangY. YuX. MaZ. WangY. ZhaoY. GuanY. XieF. ZhangQ. YaoZ. Diagnostic accuracy and value of CXCR4-targeted PET/MRI using 68 Ga-Pentixafor for tumor localization in Cushing disease.Radiology20243133e23346910.1148/radiol.233469 39688484
     [Google Scholar]
  73. O’TooleS.M. SzeW.C.C. ChungT.T. AkkerS.A. DruceM.R. WaterhouseM. PitkinS. DawnayA. SahdevA. MatsonM. ParvantaL. DrakeW.M. Low-grade cortisol cosecretion has limited impact on ACTH-stimulated AVS parameters in primary Aldosteronism.J. Clin. Endocrinol. Metab.202010510e3776e378410.1210/clinem/dgaa519 32785656
     [Google Scholar]
  74. WeiX. WuF. DongH. JingY. SongY. PangH. ChenJ. DuZ. HeW. MaL. WangY. HuJ. LiQ. YangS. MeiM. LuoS. LiaoK. ZhangY. HeY. HeY. XiaoM. PengB. 68Ga-pentixafor PET/CT in the localization diagnosis of primary aldosteronism concurrent subclinical Cushing’s syndrsome: two case reports.Endocrine20248531398140610.1007/s12020‑024‑03865‑6 38914747
     [Google Scholar]
  75. TerzoloM. BaudinA.E. ArditoA. KroissM. LeboulleuxS. DaffaraF. PerottiP. FeeldersR.A. deVriesJ.H. ZaggiaB. De FranciaS. VolanteM. HaakH.R. AllolioB. Al GhuzlanA. FassnachtM. BerrutiA. Mitotane levels predict the outcome of patients with adrenocortical Carcinoma treated adjuvantly following radical resection.Eur. J. Endocrinol.2013169326327010.1530/EJE‑13‑0242 23704714
     [Google Scholar]
  76. DreherN. HahnerS. FußC.T. SchlötelburgW. HartrampfP.E. SerflingS.E. SchirbelA. SamnickS. HiguchiT. WeichA. LapaC. RosenwaldA. BuckA.K. KircherS. WernerR.A. CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology.Eur. J. Nucl. Med. Mol. Imaging20245151383139410.1007/s00259‑023‑06547‑z 38082196
     [Google Scholar]
  77. BuckA.K. HaugA. DreherN. LambertiniA. HiguchiT. LapaC. WeichA. PomperM.G. WesterH.J. ZehnderA. SchirbelA. SamnickS. HackerM. PichlerV. HahnerS. FassnachtM. EinseleH. SerflingS. WernerR.A. Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-Pentixafor PET.J. Nucl. Med.20226311jnumed.121.26369310.2967/jnumed.121.26369335241482
     [Google Scholar]
  78. BluemelC. HahnerS. HeinzeB. FassnachtM. KroissM. BleyT.A. WesterH.J. KropfS. LapaC. SchirbelA. BuckA.K. HerrmannK. Investigating the chemokine receptor 4 as potential theranostic target in Adrenocortical cancer patients.Clin. Nucl. Med.2017421e29e3410.1097/RLU.0000000000001435 27819856
     [Google Scholar]
  79. HahnerS. HiguchiT. SerflingS.E. SamnickS. FussC.T. HeinzeB. BuckA.K. SchirbelA. FassnachtM. WernerR.A. Exploring theranostic avenues in Adrenocortical carcinoma using chemokine receptor and prostate-specific membrane antigen–directed PET/CT.Clin. Nucl. Med.202449436937010.1097/RLU.0000000000005083 38350087
     [Google Scholar]
  80. HerrmannK. SchotteliusM. LapaC. OslT. PoschenriederA. HänscheidH. LückerathK. SchrederM. BluemelC. KnottM. KellerU. SchirbelA. SamnickS. LassmannM. KropfS. BuckA.K. EinseleH. WesterH.J. KnopS. First-in-human experience of CXCR4-directed endoradiotherapy with 177 Lu- and 90 Y-Labeled Pentixather in advanced-stage Multiple Myeloma with extensive intra- and extramedullary disease.J. Nucl. Med.201657224825110.2967/jnumed.115.167361 26564323
     [Google Scholar]
  81. LapaC. HänscheidH. KircherM. SchirbelA. WunderlichG. WernerR.A. SamnickS. KotzerkeJ. EinseleH. BuckA.K. WesterH.J. GrigoleitG.U. Feasibility of CXCR4-Directed radioligand therapy in advanced diffuse large B-Cell Lymphoma.J. Nucl. Med.2019601606410.2967/jnumed.118.210997 29777009
     [Google Scholar]
  82. BuckA.K. GrigoleitG.U. KrausS. SchirbelA. HeinschM. DreherN. HiguchiT. LapaC. HänscheidH. SamnickS. EinseleH. SerflingS.E. WernerR.A. C-X-C motif chemokine receptor 4–Targeted radioligand therapy in patients with advanced T-Cell Lymphoma.J. Nucl. Med.2023641343910.2967/jnumed.122.264207 35738903
     [Google Scholar]
  83. MaurerS. HerhausP. LippenmeyerR. HänscheidH. KircherM. SchirbelA. MaurerH.C. BuckA.K. WesterH.J. EinseleH. GrigoleitG.U. KellerU. LapaC. Side effects of CXC-Chemokine receptor 4–Directed endoradiotherapy with Pentixather before hematopoietic stem cell transplantation.J. Nucl. Med.201960101399140510.2967/jnumed.118.223420 30850502
     [Google Scholar]
  84. SchloetelburgW. HartrampfP.E. KosmalaA. SerflingS.E. DreherN. SchirbelA. FassnachtM. BuckA.K. WernerR.A. HahnerS. Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma.Eur. J. Nucl. Med. Mol. Imaging202451123643365010.1007/s00259‑024‑06800‑z 38896128
     [Google Scholar]
  85. KunikowskaJ. MatyskielR. ToutounchiS. Grabowska-DerlatkaL. KoperskiŁ. KrólickiL. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?Eur. J. Nucl. Med. Mol. Imaging201441122273228010.1007/s00259‑014‑2844‑1 25027709
     [Google Scholar]
  86. LiZ. ContiP.S. Radiopharmaceutical chemistry for positron emission tomography.Adv. Drug Deliv. Rev.201062111031105110.1016/j.addr.2010.09.007 20854860
     [Google Scholar]
/content/journals/mrmc/10.2174/0113895575408753250904112417
Loading
Recent Development of CXCR4-Targeted Nuclear Medicine Research in Adrenocortical Tumors
Mini Rev Med Chem 25, 1227 (2025); https://doi.org/10.2174/0113895575408753250904112417
/content/journals/mrmc/10.2174/0113895575408753250904112417
/content/journals/mrmc/10.2174/0113895575408753250904112417
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): adrenocortical carcinomas; Adrenocortical tumors; Cushing's syndrome; CXCR4; pentixafor; PET; primary aldosteronism

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test